Biohaven Ltd.

About Biohaven Ltd.

Biohaven is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of life-changing treatments in key therapeutic areas including neuroscience, immunology, and oncology. Their mission is driven by urgency and intention to address diseases with significant unmet medical needs, focusing on patient-first culture and scientific innovation.

Products & Services

Nurtec® ODT (rimegepant):A treatment for migraine, representing a groundbreaking legacy in transforming migraine therapy.

Zavzpret® (zavegepant):Another innovative treatment for migraine, part of Biohaven's successful portfolio in neuroscience.

BHV-1300:A potential first-in-class degrader achieving over 80% sustained reductions in total IgG, currently under development.

BHV-1400:A potential first-in-class treatment for IgA Nephropathy (IgAN), achieving significant reductions in Gd-IgA1.

TYK2/JAK1 Inhibitor:A novel brain-penetrant inhibitor targeting neuroinflammation, in Phase 2/3 trials for early Parkinson's disease.

Trop2 and FGFR3 Antibody Drug Conjugates (ADCs):Innovative oncology treatments incorporating novel TopoIx payload, with potential to treat a wide variety of tumors.

Specialties

Neuroscience Immunology Oncology Clinical Trials Drug Development Platforms Migraine Treatment Neuroinflammation Antibody Drug Conjugates (ADCs)

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Debt T: - FT: Debt	A: 600000000 MR: - FA: up to $600 million FAN: 600000000	D: 2025-04-28 FD: 2025-04-28	1 investors

Debt Latest

2025-04-28

$600.0M

1 investor (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

R

Richard B. Lipton

Edwin S. Lowe Professor and Vice Chair of Neurology, Professor of Epidemiology and Population Health, and Professor of Psychiatry and Behavioral Sciences at Albert Einstein College of Medicine

J

John Krystal

Head of Scientific Advisory Board and Co-inventor of Yale IP

G

Gerard Sanacora

Professor and Director of the Yale Depression Research Clinic

D

David Spiegel

Professor of Chemistry and Pharmacology

J

Joel Elkes

R

Robert L. McNeil

View 53 more team members with Pro

Unlock Full Team Directory

Recent News

Biohaven Ltd. Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised